Head to Head Comparison: OptimizeRx (NASDAQ:OPRX) and Ucommune International (NASDAQ:UK)

OptimizeRx (NASDAQ:OPRX) and Ucommune International (NASDAQ:UK) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Risk & Volatility

OptimizeRx has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Ucommune International has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Valuation & Earnings

This table compares OptimizeRx and Ucommune International”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$71.52 million	1.24	-$17.57 million	($1.33)	-3.61
Ucommune International	$64.76 million	0.01	-$690,000.00	N/A	N/A

Ucommune International has lower revenue, but higher earnings than OptimizeRx.

Analyst Ratings

This is a summary of current recommendations and price targets for OptimizeRx and Ucommune International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0	3	6	0	2.67
Ucommune International	0	0	0	0	0.00

OptimizeRx currently has a consensus price target of $9.06, indicating a potential upside of 88.80%. Given OptimizeRx’s stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than Ucommune International.

Institutional and Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 36.9% of Ucommune International shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by company insiders. Comparatively, 14.2% of Ucommune International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares OptimizeRx and Ucommune International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-27.41%	-4.92%	-3.41%
Ucommune International	N/A	N/A	N/A

Summary

OptimizeRx beats Ucommune International on 7 of the 12 factors compared between the two stocks.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About Ucommune International

Ucommune International Ltd manages and provides agile office spaces in China. It operates self-operated and asset-light models. The company also provides individual services, such as catering, fitness, healthcare, training, and entertainment; general corporate services, such as corporate secretary, human resources, legal, finance, IT support, and tax services; incubation and corporate venturing services; design and build services; advertising and branding services; and related services. It serves individuals and enterprises. The company operates under the Ucommune brand. Ucommune International Ltd was founded in 2015 and is based in Beijing, the People's Republic of China.